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Adeno-associated virus type 2 nonstructural protein Rep78 [621 amino acids (aa) long] affects the expression of various
cellular and viral genes. In this study we examined the effects of Rep78 on expression of the luciferase gene from the human
cytomegalovirus immediate-early promoter in HeLa cells and on translation of RNA encoding luciferase in rabbit reticulocyte
lysate. When Rep78 and luciferase were coexpressed, the luciferase activity decreased despite increased levels of luciferase
mRNA in the cells. Purified Rep78 or Rep68 fused with Escherichia coli maltose binding protein suppressed translation of
luciferase RNA in vitro, but Rep52/40 fusion proteins did not. A mutated Rep78, which is 520 aa long and truncated at its
C-terminus, did suppress the in vitro translation, whereas a similarly truncated Rep78 of 420 aa did not. The results indicate
that Rep78/68 function to suppress gene expression through translation inhibition, which requires the N-terminal region
contained within aa 1–520. © 2000 Academic Press
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Adeno-associated virus (AAV) type 2, a human parvo-
virus, is a nonenveloped small virus with a genome of 4.7
kb of single-stranded linear DNA. Propagation of AAV
relies on the presence of a helper virus such as adeno-
virus, herpes simplex virus, and human cytomegalovirus.
Without a helper virus, AAV integrates into the host ge-
nome, preferentially in a region on the q arm of human
chromosome 19, and is maintained as a latent provirus
(Berns and Giraud, 1996). When AAV and a helper virus
are coinfected to cell culture, AAV can propagate with
suppression of helper virus propagation (Carter et al.,
1979; Heilbronn et al., 1990). The unique life cycle of AAV
is regulated through the functions of viral nonstructural
Rep proteins.
The AAV rep gene is transcribed from two promoters
and encodes four overlapping multifunctional proteins,
Rep78, 68, 52, and 40 (Mendelson et al., 1986) (Fig. 1).
Both Rep78 and Rep68 transcripts are initiated from the
promoter at map unit 5 (P5), and the first 529 amino acids
of Rep78 and Rep68 are identical (Srivastava et al., 1983).
These proteins that have ATP-dependent DNA/DNA and
DNA/RNA helicase activities (Im and Muzyczka, 1990;
Wonderling et al., 1995; Zhou et al., 1999), a site-specific
endonuclease (Im and Muzyczka, 1990; Snyder et al.,
1990), and the ability to bind to specific sites within the
AAV terminal hairpin DNA (McCarty et al., 1994; Chiorinis
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19et al., 1994) are required for AAV DNA replication (Her-
monat et al., 1984; Tratschin et al., 1984) and for integra-
tion of the AAV genome into host cell DNA (Weitzman et
al., 1994; Linden et al., 1996). Rep52 and Rep40 are
ranscribed from the promoter at map unit 19 (P19) (Sri-
astava et al., 1983), and these proteins are required for
he accumulation of single-stranded progeny genomes
or encapsidation (Chejanovsky and Carter, 1989;
istuba et al., 1995; Prasad and Trempe, 1995).
AAV Rep proteins regulate the expression of AAV
enes and affect expression from a variety of heterolo-
ous promoters. Rep78/68 down-regulate gene expres-
ion from the P5 and the P19, whereas in the presence of
elper adenovirus these proteins stimulate expression
rom the P19 and the promoter at map unit 40 (P40,
romoter for genes encoding capsid proteins) (Labow et
l., 1986; McCarty et al., 1991; Pereira et al., 1997). In 293
cells, a human cell line transformed with adenovirus, Rep
proteins stimulate transcription of the reporter gene from
the P40 with reduced activity of the reporter enzyme
(Trempe and Carter, 1988). Rep78/68 also have the ca-
pacity to affect gene expression from human promoters
for c-myc, c-fos, c-H-ras, the human immunodeficiency
virus-1 long terminal repeats (HIV-LTR), and the human
papillomavirus type 18 long control region (HPV-18 LCR)
(Antoni et al., 1991; Batchu and Hermonat, 1995; Her-
monat, 1991, 1994; Oelze et al., 1994; Horer et al., 1995).
lthough these studies suggest that Rep78/68 repress
ranscription from heterologous promoters, a recent
tudy shows that Rep68 increases mRNA levels tran-
cribed from the human cytomegalovirus immediate-
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197AAV Rep78 SUPPRESSES TRANSLATIONearly promoter (CMV-IE) (Wonderling et al., 1997). How
ep proteins regulate gene expression from heterolo-
ous promoters is yet to be elucidated.
In this study, we examined the effect of Rep78 on the
ranscription of the renilla luciferase gene from CMV-IE
n HeLa cells transfected with plasmids expressing re-
illa luciferase and Rep78. Rep78 induced the increase
f mRNA levels as reported for Rep68 previously (Won-
erling et al., 1997) but repressed the luciferase activity,
ndicating that suppression of gene expression by Rep78
ccurred posttranscriptionally. More directly, the addition
f Rep78/68, but not Rep52/40, to the in vitro translation
system inhibited translation from RNA encoding firefly
luciferase. Analysis of the truncation mutants of Rep78
indicated that the N-terminal region required for the
suppressive function is within amino acids 1 to 520.
RESULTS AND DISCUSSION
Suppression of gene expression from heterologous
promoters by Rep78
The effects of Rep78 and Rep52 on expression of
reporter genes under the control of three viral promoters,
CMV-IE, HPV16-LCR, and adenovirus type 2 major late
promoter (Ad2ml) were examined. CMV, HPV, and Ad2
can be helper viruses for AAV propagation and these
promoters do not contain Rep-binding sequences. HeLa
cells (4 3 105) were transfected with a mixture of plas-
mids consisting of 0.02 mg of one of the expression
lasmids for reporter genes [the plasmid for the renilla
uciferase gene driven by CMV-IE (pRL-CMV), by HPV16-
FIG. 1. Genome organization and Rep proteins of AAV type 2. Three
promoters at map units 5, 19, and 40 (open circles) and inverted
terminal repeats (ITR; filled box at both ends) are shown at the top. The
N-terminal region specific for Rep78/68 (aa 1 to 225), the central region
common to all four Reps (aa 225 to 529), the major intron of AAV type
2, and the C-terminal amino acids specific for Rep68/40 are presented.
The mutants differentially truncated at their C-terminus are used in this
study (bottom three rows). Rep78370, Rep78440, and Rep78520 are com-
posed of aa 1 to 370, aa 1 to 440, and aa 1 to 520 of Rep78, respectively.CR (pLCR-RL), and by Ad2ml (pAd2ml-RL) and the plas-
id for the b-galactosidase (b-gal) gene driven by
w
pCMV-IE (pCMV-b)] and 0, 0.02, 0.06, and 0.2 mg of CMV-
IE-driven expression plasmid for Rep78 (pCMV78) or
Rep52 (pCMV52). Expression of Rep78 and Rep52 in
HeLa cells transfected with pCMV78 and pCMV52, re-
spectively, was confirmed by immunoblotting analysis
using anti-Rep antibody (anti-AAV Rep protein mouse
monoclonal antibody, Clone 226.7, Progen Biotechnik
GmbH, Heidelberg, Germany) (data not shown). Activities
of renilla luciferase were measured at 30 h after trans-
fection and b-gal activity was measured at 48 h (Fig. 2).
The data clearly show that, whereas Rep52 did not sup-
press expression, Rep78 suppressed expression of the
reporter genes from these viral promoters used in a
dose-dependent manner.
FIG. 2. Effect of Rep78 (A) and Rep52 (B) on expression of renilla
uciferase from cytomegalovirus immediate-early promoter (pRL-CMV),
rom human papillomavirus type 16 long control region (pLCR-RL), and
rom adenovirus type 2 major late promoter (pAd2ml-RL) and b-galac-
osidase from cytomegalovirus immediate-early promoter (pCMV-b).
uciferase or b-galactosidase activity of lysate of HeLa cells trans-
ected with a mixture of a Rep plasmid and an expression plasmid for
ep protein at different ratios was measured and enzyme activities
rom cells transfected with a Rep plasmid relative to those obtainedl
f
f
t
L
f
R
fithout a Rep plasmid were calculated. Data obtained from four inde-
endent transfections are presented with standard deviations (bars).
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198 TAKEUCHI ET AL.Effects of Rep78 on transcription of the luciferase
gene from the CMV-IE promoter
To analyze the effect of Rep78 on transcription from
CMV-IE, the levels of transcripts from pRL-CMV in the
presence of Rep78 were measured by real-time PCR with
an ABI PRISM 7700 (PE Applied Biosystems, Foster City,
CA) (Fink et al., 1998). Three sets of HeLa cell cultures
were transfected with a mixture of pRL-CMV and
pCMV78 (or pCMVb) at a ratio of 1 to 10, and total DNA,
total mRNA, and cell lysate were prepared from each
culture set at 24, 30, and 48 h after transfection. pRL-
CMV in total DNA and mRNA transcribed from pRL-CMV
in total mRNA were quantified and renilla luciferase
activities in the lysate were measured. Since Rep78
might affect its own expression in a feedback loop, we
attempted to analyze the earliest events induced by
Rep78. Levels of luciferase mRNA were normalized to
levels of pRL-CMV and levels of mRNA in HeLa cells with
Rep78 relative to those without Rep78 are shown in Fig.
3A. At 24 and 30 h the mRNA was more abundant in the
cells containing Rep78 than in those containing b-gal,
ndicating that Rep78 increased mRNA levels transcribed
rom CMV-IE as reported previously (Wonderling et al.,
997). However, luciferase activity in the lysate of cells
ontaining Rep78 was comparable to that in the lysate
ontaining b-gal at 24 h (Fig. 3B) and was lower than
hose expected from the levels of mRNA (Fig. 3A). The
ata strongly suggest that posttranscriptional steps for
he luciferase gene expression are blocked by Rep78.
uppression of translation in vitro by Rep proteins
Suppression of translation by Rep proteins was exam-
ned with an in vitro translation system composed of
abbit reticulocyte lysate and commercially purchased
irefly luciferase RNA (Promega Co. Ltd.). Four Rep pro-
eins, maltose binding protein (MBP)–Rep78, MBP–
ep68, MBP–Rep52, and MBP–Rep40, were bacterially
xpressed as fusion proteins with MBP, purified by affin-
ty column chromatography (Fig. 4A), and added to the
ranslation system to test their function.
Addition of MBP–Rep78 to the reaction mixture re-
ulted in the dose-dependent suppression of luciferase
ctivity (Fig. 4B). Since luciferase activity produced in the
ystem was not affected by adding MBP–Rep78 to the
ixture after translation reaction ceased (data not
hown), it was not the luciferase assay system on which
ep78 exerted its effect.
Suppressive effects of the other three Rep proteins,
ep68, Rep52, and Rep40, on the translation reaction in
he in vitro system were tested (Fig. 4C). Rep68 sup-
ressed translation as effectively as Rep78, but Rep52
nd Rep40 did not. Thus, the suppressive activity for
ranslation was common to the “large” Rep proteins but
ot shared by the “small” Rep proteins, indicating that the
-terminal region of Rep78/68 not present in Rep52/40
s
has necessary for translational suppression. The results
ere concordant with those of cotransfection assays,
ndicating that, whereas Rep52 did not, Rep78 sup-
ressed the expression of reporter genes in the cells
Fig. 2).
Three truncation mutants of Rep78, Rep78371, Rep78440,
and Rep78520 (Fig. 1), were constructed and examined for
heir suppressive effect on translation (Fig. 4C). Rep78520,
hich has a stop codon at amino acid 521, retained the
FIG. 3. (A) Relative quantity of luciferase mRNA in the presence of
Rep78 compared to that in the presence of b-galactosidase. HeLa cells
ere transfected with a mixture of expression plasmids for renilla
uciferase and for b-galactosidase or a mixture of expression plasmids
or renilla luciferase and for Rep78. mRNA were isolated at 24, 30, and
8 h after transfection and quantities of luciferase mRNA in the total
RNA samples were measured with an ABI Prism 7700 sequence
etector (PE Applied Biosystems). Normalized mRNA levels in the
resence of Rep78 (designated Rep78 in the figure) compared to those
n the presence of b-galactosidase (b-gal in the figure) are presented.
ata obtained from three independent transfections are presented with
tandard deviations (bars). (B) Relative luciferase activity in the pres-
nce of Rep78 compared to that in the presence of b-galactosidase.
Luciferase activity of lysate of HeLa cells transfected with a mixture of
expression plasmids similar to the experiment described above was
measured.uppressive activity but the other two truncation mutants
ad lost it. Therefore, the C-terminal 101-aa region of
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199AAV Rep78 SUPPRESSES TRANSLATIONRep78 was not necessary but the stretch from aa 1 to
FIG. 4. Effect of Rep proteins on in vitro translation. (A) Electrophoresis
of bacterially expressed Rep proteins. Purified fusion proteins (2 mg) were
lectrophoresed on SDS–8% polyacrylamide gel and stained with Coo-
assie brilliant blue. Molecular weight marker (lane M), MBP (lane 1),
BP–Rep78 (lane 2), MBP–Rep68 (lane 3), MBP–Rep52 (lane 4), MBP–
ep40 (lane 5), MBP–Rep78371 (lane 6), MBP–Rep78440 (lane 7), and MBP–
ep78520 (lane 8). (B) Activities of luciferase in vitro translated in the
resence of Rep78. RNA encoding renilla luciferase (0.01 mg, purchased
from Promega Corp.) and purified MBP-78 (0 to 4 mg) were added to rabbit
reticulocyte lysate and activity of the synthesized luciferase was mea-
sured. Data obtained from three independent experiments are presented
with standard deviations (bars). (C) Activities of luciferase in vitro trans-
lated in the presence of Rep proteins. RNA encoding renilla luciferase
(0.01 mg, Promega Corp.) and 2 mg of the purified MBP-Rep protein was
added to rabbit reticulocyte lysate and activity of synthesized luciferase
was measured. Translated in the presence of no fusion protein (lane 1),
MBP (lane 2), MBP–Rep78 (lane 3), MBP–Rep68 (lane 4), MBP–Rep52
(lane 5), MBP–Rep40 (lane 6), MBP–Rep78371 (lane 7), MBP–Rep78440 (lane
), and MBP–Rep78520 (lane 9). Data obtained from three independent
xperiments are presented with standard deviations (bars).520 was indicated to contain some functional region(s)
necessary for the translational suppression.
sIn summary, this study has shown that AAV Rep78
increases the level of mRNA transcribed from CMV-IE in
cells soon after transfection and that Rep78/68 repress
translation of RNA in vitro. The data are consistent with
the previous findings that Rep proteins increase the level
of chloramphenicol acetyltransferase mRNA transcribed
from the P40 while apparently suppressing the enzyme
activity in 293 cells (Trempe and Carter, 1988). A part of
the Rep proteins are detectable in the cytoplasm (Im and
Muzyczka, 1990), although the proteins localize mainly in
the nuclei (Mendelson et al., 1986; Trempe et al., 1987). It
is, therefore, very likely that Rep78/68 inhibit expression
of proteins directed under the control of CMV-IE through
suppression of translation.
The significance of the translational suppression by
Rep proteins in relation to the life cycle of AAV is unclear
at present. It is conceivable, however, that the function of
Rep proteins to affect gene expression from heterolo-
gous viral promoters may contribute, at least partly, to
maximum utilization of cellular resources for propagation
of AAV in a cell coinfected with a helper virus. If this is
the case, it is important to know the mechanisms that
allow the protein synthesis directed by AAV to escape
from the translational suppression.
AAV is one of the most promising gene therapy vec-
tors, with its stability, low antigenicity, apparent lack of
pathogenicity, and ability to integrate into the unique
region of chromosome 19 (AAVS1). Since the integration
of AAV into AAVS1 seems not to be pathogenic to hu-
mans, AAVS1 may be an ideal region for insertion of the
vector. However, the rep gene has been deleted from the
recombinant AAV vectors used in clinical trials so far
(Flotte et al., 1993), because the pivotal Rep proteins are
thought to be potentially cytotoxic (Hermanns et al., 1997;
Kube et al., 1997). To give AAV vectors the capability of
introducing therapeutic genes into AAVS1, the properties
of Rep proteins should be dissected thoroughly and, if
possible, functions not necessary for the site-specific
integration should be removed. For that purpose, exten-
sive studies of the structure and function of Rep proteins
are required.
MATERIALS AND METHODS
Plasmids
The expression plasmid for renilla luciferase from hu-
man CMV-IE (pRL-CMV) was purchased from Promega
Corp. (Madison, WI). The plasmid for b-gal from CMV-IE
as purchased from Clontech Laboratories, Inc. (Palo
lto, CA). The plasmid for renilla luciferase from HPV-16
ong control region was constructed by insertion of a
NA fragment of nt 7010 to 561 of HPV-16 (the HPV
equence Database of Los Alamos National Laboratory)
nto pRL-null (Promega Corp.). pAd2ml-RL was con-
tructed by replacement of the b-gal gene of pAD-b
(Clontech Laboratories, Inc.) with the renilla luciferase
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200 TAKEUCHI ET AL.gene. pCMV78 was constructed by replacement of the
b-gal gene of pCMV-b with the rep78 gene (from nt 321
o 2186 of AAV2; GenBank Accession No. AF043303). To
llow pCMV78 to express Rep78 protein alone the fol-
owing modifications of rep gene were made by PCR-
ased mutagenesis: (i) to destroy the P19 TATA box,
ATTTAA from nt 843 to 849 was changed to TACCTGA;
ii) to destroy the P40 TATA box, TATAA from nt 1823 to
827 was changed to CATCA; (iii) to destroy P40, TCA
rom nt 1851 to 1853 was changed to AGC; (iv) to destroy
he splice donor site, CAGG from nt at 1904 to 1907 was
hanged to TCGA; and (v) to destroy the splice acceptor
ite, GAT from nt 2227 to 2229 was changed to CAA.
CMV52, the expression plasmid for Rep52, was con-
tructed by removal of the region from nt 321 to 992.
tructures of newly constructed plasmids were verified
y nucleotide sequencing with an ABI Prism 310 autose-
uencer (PE Applied Biosystems).
usion proteins
Rep proteins fused with MBP were expressed using
acterial expression plasmid pMAL-c2 (New England
ioLabs, Inc., Beverly, MA). A DNA fragment encoding
ep78 was isolated from pCMV78 and inserted into
MALc2 to generate pMAL–Rep78. pMAL–Rep68 and
MAL–Rep52 were constructed by removal of the re-
ions from nt 1907 to 2227 and nt 321 to 992 from
MAL–Rep78, respectively. pMAL–Rep40 was con-
tructed by removal of the region from nt 321 to 992 from
MAL–Rep68. Truncation mutants of Rep78 were con-
tructed by oligonucleotide-directed mutagenesis using
he Mutan Super Express Km Kit (TaKaRa Co. Ltd., Kyoto,
apan). pMAL–Rep78371, pMAL–Rep78440, and pMAL–
Rep78520 have stop codons at aa 372, 441, and 521,
respectively.
MBP–Rep proteins produced in Escherichia coli JM109
transformed with each of the pMAL–Rep plasmids were
extracted by brief sonication, and then the extracted
proteins were purified by affinity column chromatography
according to the manufacturer’s protocol. The purified
proteins were dialyzed against buffer [25 mM NaCl, 2.5
mM Tris–HCl (pH 7.4), 0.125 mM EDTA] and quantitated
with a DC Protein Assay Kit (Bio-Rad Laboratories, Her-
cules, CA). MBP–Rep78 prepared in this study had DNA/
DNA helicase activity, indicating its correct folding (data
not shown).
Transfection
HeLa S3 cells, cultured in Dulbecco’s modified Eagle’s
medium supplemented with antibiotics and 10% fetal calf
serum, were plated at a density of 4 3 104 per well on
24-well plates or at 4 3 105 per well on 6-well plates 24 h
rior to transfection. For assay of luciferase or b-galac-
tosidase activities, cells in 24-well plates were trans-
fected with a mixture of plasmids consisting of 0.02 mg ofeporter plasmid and 0 to 0.2 mg of pCMV78 or pCMV52.
Total DNA for transfection was adjusted to 0.22 mg per
well with pCMVb or pCMV-C, which express a biologi-
ally inactive short peptide from CMV-IE (unpublished
ata), in the case where pCMVb was used as the re-
orter plasmid. For extraction of DNA or mRNA for real-
ime PCR, cells in 6-well plates were transfected with a
ixture of 0.035 mg of pRL-CMV and 0.35 mg of either
CMV78 or pCMVb. Effectene Transfection Reagent
(Qiagen GmbH, Hilden, Germany) was used, following
the manufacturer’s instructions.
Assay of luciferase activity
Renilla and firefly luciferase activity of the lysate of
HeLa cells transfected with the expression plasmids
were measured with a Dual-Luciferase Reporter Assay
System (Promega Corp.) with an LB96V luminometer
(Berthold Co. Ltd., Wildbad, Germany). b-Gal activity of
the cellular lysate was determined with Luminescent
b-Galactosidase Detection Kit II (Clontech Laboratories)
using the luminometer. Enzyme activities in the lysates
with Rep protein relative to those without Rep protein
were calculated using data obtained from three to four
independent experiments. Since the normalization of the
luciferase activities to the amount of luciferase plasmid
DNA recovered from the lysates did not affect the results,
the results without the normalization are presented.
Real-time PCR
Total DNA was isolated from cells with QIAamp (Qia-
gen GmbH) and digested with RNase A. mRNA was
isolated with a QuickPrep Micro mRNA Purification Kit
(Amersham Pharmacia Biotech, Uppsala, Sweden) and
treated with RT-grade DNase I (Nippon Gene, Tokyo,
Japan). For mRNA quantitation, first-strand cDNA was
synthesized in a 50-ml mixture [50 ng of mRNA, 13
aqMan RT buffer (PE Applied Biosystems), 5.5 mM
gCl2, 500 mM each dNTP (dATP, dCTP, dGTP and
TTP), 2.5 mM random hexamers, 20 U RNase inhibitor,
nd 62.5 U MultiScribe reverse transcriptase (PE Applied
iosystems)] by incubation at 25°C for 10 min, at 48°C
or 30 min, and at 95°C for 5 min and then cooled to room
emperature. Five microliters of the cDNA or 5 ng of total
NA was included in a 25-ml PCR mixture containing
12.5 ml of TaqMan universal PCR master mix (PE Applied
iosystems). For renilla luciferase plasmid and cDNA
uantitation the following oligonucleotides were used
final concentration in parentheses): forward primer, 59-
CTCTTCTTATTTATGGCGACATGT-39 (200 nM); reverse
primer, 59-GCCTGATTTGCCCATACCAA-39 (800 nM); and
probe, 59-FAM (6-carboxyfluorescein)-TGCCACATATT-
GAGCCAGTAGCGCG-TAMRA(6-carboxytetramethylrho-
damine)-39 (200 nM). For b-actin DNA and GAPDH mRNA
quantitation, primers and probes of TaqMan b-actin con-
trol reagent and TaqMan GAPDH control reagent (PE
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201AAV Rep78 SUPPRESSES TRANSLATIONApplied Biosystems), respectively, were used. The mea-
surement was done in an ABI Prism 7700 sequence
detector (PE Applied Biosystems) by PCR consisting of
50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for
15 s, and 60°C for 1 min. Standard curves for luciferase
DNA and mRNA, for b-actin DNA, and for GAPDH mRNA
were generated using plasmid pRL-CMV, total human
DNA, and cDNA synthesized from total cellular RNA,
respectively, and analysis of data was done according to
the manufacturer’s instructions. Levels of pRL-CMV and
luciferase mRNA in cells were normalized using b-actin
DNA and GAPDH mRNA as a standard, respectively, and
then levels of luciferase mRNA were normalized to levels
of pRL-CMV.
In vitro translation
A reaction mixture (25 ml) containing 17.5 ml of the
Rabbit Reticulocyte Lysate System (Promega Corp.), 0.01
mg of Luciferase Control RNA (purchased from Promega
Corp.), and MBP-Rep proteins was incubated at 30°C for
90 min, snap-frozen in liquid nitrogen to stop the reac-
tion, and kept on ice. To measure firefly luciferase activ-
ity, 20 ml of the sample, which was diluted at 1 to 8 using
he passive lysis buffer (Promega Corp.), was used.
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